课题基金 / 基金详情

DC-targeted DNA vaccines

DC-targeted DNA vaccines
DC 靶向 DNA 疫苗
批准号:
7774820
负责人:
Ralph Marvin Steinman
金额:
$43.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-25 至 2014-08-31

项目摘要

项目成果

Ralph Marvin Steinman的其他基金

相似基金

相关文献

中文摘要
翻译
我们已经开始了一种新的疫苗接种方法。我们直接利用树突状细胞(DC)的特性来 提高疫苗效力,重点是T细胞介导的免疫。之前我们设计了蛋白质 疫苗,以改善艾滋病毒Gag在小鼠树突状细胞的传递。定向或定向递送GAG 树突状细胞表面DEC-205受体的单抗相对于 非靶向蛋白以及在小鼠模型中的保护作用。DC靶向的一个较新的例子涉及DNA 疫苗,正如将在这里研究的那样。疫苗编码一种由单链Fv组成的融合蛋白 抗树突状细胞抗体与HIV Gag融合。免疫保护效果提高约100倍。我们有四个目标 与几个主要合作者一起研究机制和改进DNA疫苗:1)DNA递送 目前,对DC的疫苗配置是通过诱导的免疫间接监测的。为了获得 关于小鼠DC摄取和处理疫苗的直接数据,我们将a)用敏感的 我们开发的称为“ollas”的系统;b)使用MHC多肽的抗体,以及c)从 目标DC以识别呈现的多肽。2)通过这些检测,我们将比较不同的DC 将疫苗蛋白定向到这些关键呈递细胞的受体。我们准备了杂交瘤和 将重链和轻链克隆到额外的DC受体上,如Langerin/CD207和DC-Sign/CD209,因此 我们可以制备针对其他DC靶点的单链FV Gag融合DNA疫苗。3)改进DNA 疫苗效力在DC的水平上,我们将研究不同DC成熟的免疫刺激效应 刺激,包括优先连接激活FcyR的Ig C区序列。4)扩展基于DC的 以SIV猕猴模型的DNA疫苗,我们已经制备了抗人DEC-205抗体, 与猴子DEC-205反应,并在MHC I类分子上介导GAG的高效交叉呈现,我们有 制备人DEC-205转基因小鼠以确保抗恒河猴/人单链DEC成功 在体内靶向和呈递SIV抗原。这将使我们能够确定单链抗体Gag融合DNA 疫苗成功地针对猴子淋巴组织中的DC。
英文摘要
We have begun a new approach to vaccines. We directly harness the properties of dendrific cells (DCs) to improve vaccine efficacy, with emphasis on T cell mediated immunity. Previously we designed protein vaccines to improve delivery of HIV gag to DCs in mice. Directed or targeted delivery of gag within a monoclonal antibodies to the DEC-205 receptor on DCs gave a large increase in immunogenicity relative to nontargeted protein as well as protection in a mouse model. A newer example of DC targeting involves DNA vaccines, as will be studied here. The vaccine encodes a fusion protein comprised of a single chain Fv antibody to DCs fused to HIV gag. Immunizing and protective efficacy increased ~100 fold. We have 4 aims to study mechanisms and improve DNA vaccines along with several key collaborators: 1) Delivery of DNA vaccine anfigens to DCs is currently monitored indirectly, by virtue ofthe immunity that is induced. To gain direct data on DC uptake and processing of vaccines in mice, we will a) tag vaccine proteins with a sensitive system we developed called "OLLAS"; b) use antibodies to MHC-peptide, and c) isolate MHC products from targeted DCs to identify the presented pepfides. 2) With these assays we will then compare different DC receptors for targeting vaccine protein to these critical presenting cells. We have prepared hybridomas and cloned the heavy and light chains to additional DC receptors like Langerin/CD207 and DC-SIGN/CD209, so that we can prepare single chain Fv gag fusion DNA vaccines to other DC targets. 3) To improve DNA vaccine efficacy at the level of DCs, we will study the immunostimulatory effects of different DC maturation stimuli, including Ig C region sequences that preferenfially ligate activating FcyR. 4) To extend DC-based DNA vaccines to the SIV macaque model, we already have prepared anti-human DEC-205 antibodies that react with monkey DEC-205 and mediate efficient cross presentation of gag on MHC class I, and we have prepared human DEC-205 transgenic mice to ensure that anti-rhesus/human single chain DEC successfully targets and presents SIV antigens in vivo. This will allow us to determine if single chain Fv gag fusion DNA vaccines successfully target to DCs in monkey lymphoid tissues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DETECTION OF MHC CLASS II PEPTIDES
  • 批准号:
    8361586
  • 项目类别:
  • 资助金额:
    $2.18万
  • 财政年份:
    2011
  • 负责人:
    Ralph Marvin Steinman
  • 依托单位:
FACS
  • 批准号:
    7645166
  • 项目类别:
  • 资助金额:
    $19.8万
  • 财政年份:
    2008
  • 负责人:
    Ralph Marvin Steinman
  • 依托单位:
Dendritic cells induce tolerance to pancreatic islets
  • 批准号:
    7645165
  • 项目类别:
  • 资助金额:
    $34.25万
  • 财政年份:
    2008
  • 负责人:
    Ralph Marvin Steinman
  • 依托单位:
FACS
  • 批准号:
    7300785
  • 项目类别:
  • 资助金额:
    $19.28万
  • 财政年份:
    2007
  • 负责人:
    Ralph Marvin Steinman
  • 依托单位:
海外基金